[Stock Analysis] A 4-Year Investor’s Deep Dive into Central Vaccine (086960): Financials, Stock Trends, DART Filings on Aquaculture Vaccines, Pet CMO, and China Export Outlook

EQUITY RESEARCH KOSDAQ: 086960 (Central Vaccine)

Central Vaccine (086960): 4-Year Investor Deep Dive
DART Aquaculture Filings & Pet CMO / China Export

DART Disclosure Analysis on Flounder Vaccines, Pet CMO Potential, and China Market Approval Catalysts

DART FILINGS Flounder Vaccines

PET MARKET Canishat & CMO

GLOBAL EXPANSION China Approvals

[Stock Analysis] A 4-Year Investor’s Deep Dive into Central Vaccine (086960): Financials, Stock Trends, DART Filings on Aquaculture Vaccines, Pet CMO, and China Export Outlook

---

1. Introduction: Revisiting Central Vaccine (086960), a Pioneer in Animal Biologics

Boasting a long history in South Korea's veterinary medicine and vaccine industry, Central Vaccine (KOSDAQ: 086960) (also known as Cavac) is a specialized biologicals company responsible for essential preventive healthcare across livestock, aquaculture, and the rapidly growing companion animal sector.

Although it receives relatively less mainstream attention from institutional investors compared to large human pharmaceutical companies in the biotech sector, Central Vaccine holds a unique technological barrier to entry by manufacturing essential biological goods designed to prevent livestock and marine animal epidemics.

This post presents an in-depth analysis of Central Vaccine's corporate structure, strategic direction, financial performance, and stock price trajectory. Furthermore, it thoroughly verifies the current status of aquaculture vaccine R&D based on official DART disclosures and public records. Finally, as a long-term shareholder holding the stock for 4 years, I will share candid reflections and personal investment theses regarding three key growth catalysts: overseas (China) exports, companion animal (Pet) vaccines/CMO, and aquaculture (flatfish/flounder) vaccines.

---

2. Company Overview & Business Structure: From Swine Core to Multi-Species Diversification

Established in 1968 and listed on the KOSDAQ market in 2003, Central Vaccine engages primarily in the research, development, manufacturing, and sale of veterinary biological products (vaccines). The company's business model is divided into 5 main animal target sectors:

• Swine Vaccines: The central pillar of total company revenue. Supplies vaccines critical to pig farm productivity, including Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Epidemic Diarrhea (PED), and Porcine Circovirus Type 2 (PCV2).
• Poultry Vaccines: Owns the flagship 'Poulshot' brand, providing protection against Avian Influenza (AI), Newcastle Disease (ND), and Infectious Laryngotracheitis (ILT).
• Bovine Vaccines: Vaccine lineup designed to prevent respiratory and digestive infectious diseases in cattle.
• Companion Animal Vaccines: Manufactures core vaccines under the 'Canishat' (dog) and 'Felishat' (cat) brands, covering DHPPL combination, Rabies, and Kennel Cough vaccines.
• Aquaculture & Other Biologics: Develops and sells vaccines for farmed fish such as olive flounder (flatfish), alongside animal healthcare products, diagnostic kits, and sanitary items.

[Central Vaccine Core Lineup by Animal Segment]
├── Swine Vaccines (PED, PRRS, PCV2, etc.) ──▶ [Largest Revenue Share / Financial Backbone]
├── Poultry & Bovine Vaccines (Poulshot, Calfshot) ──▶ [Stable Domestic Market Share]
├── Companion Animal Vaccines (Canishat, Felishat) ──▶ [High-Margin Growth Engine / CMO Potential]
└── Aquaculture Vaccines (Olive Flounder Streptococcosis, etc.) ──▶ [Future Eco-Friendly Farming Asset]

---

3. Business Strategy & R&D Capability: Technology-Driven Management

One of Central Vaccine's core strengths is its commitment to maintaining a high **R&D expenditure ratio of 7% to 10% relative to total annual revenue**. Rather than chasing short-term earnings volatility, the company consistently adheres to a technology-centric strategy of accumulating bio-technological capabilities.

1. Development of Next-Generation Recombinant Vaccines: To overcome the limitations of traditional killed or live vaccines, the company utilizes recombinant DNA technology and antigen purification techniques to continuously launch safer products with higher immunogenicity.
2. Expansion of Combination Vaccines: To alleviate the injection labor and stress burdens on livestock farmers, Central Vaccine is widening its portfolio of combination vaccines that confer multi-pathogen immunity through a single injection.
3. Global Market Expansion & China Product Approvals: Moving beyond Southeast Asian markets such as Vietnam, the Philippines, and Indonesia, the company has been actively conducting local clinical trials and regulatory approval procedures to enter **China**, the world's largest swine market.

---

4. [DART Filing Verification] Status of Aquaculture (Olive Flounder / Flatfish) Vaccine Development

Farmed fish—specifically **olive flounder (flatfish, known locally as Kwangeo)**—represents the single most important species in South Korea's raw fish (sashimi/sushi) dining culture. However, high-density aquaculture environments cause annual mass mortalities from bacterial and viral pathogens such as Streptococcosis, Edwardsiellosis, Scuticociliatosis, and Viral Nervous Necrosis (VNN).

Fact-checking Central Vaccine’s long-standing **aquaculture vaccine development history and current status** via DART (Data Analysis, Retrieval and Transfer System) filings and official channels reveals the following:

① DART Disclosures & National R&D Project Participation

Central Vaccine previously participated in national research initiatives organized by the Ministry of Oceans and Fisheries and the Animal and Plant Quarantine Agency (APQA) to develop trivalent and tetravalent combination vaccines for flounder, as well as vaccines against Scuticociliatosis. A review of Central Vaccine's DART Annual Business Reports ('Section II. Business Description - 5. Research & Development Activities') confirms continuous disclosure of aquatic biological development projects and licensing milestones [Reference 1].

② Product Licensures & Commercialization Status

According to the APQA Animal Medical Product Management System and Central Vaccine’s official product portfolio, the company holds official product licenses for **Olive Flounder Streptococcosis and Edwardsiellosis preventive vaccines** and maintains registered products on the market [Reference 2, 3].

③ Historical Bottlenecks & Current Market Limitations

Analyzing company disclosures and trade press indicates that despite product launch, aquaculture vaccine revenue growth has remained modest due to structural friction:

• Methodological Constraints: Ingestion (feed-mixed) vaccines offer low efficacy compared to **individual manual injection**, which requires significant labor and cost to inject tens of thousands of fish individually.
• Traditional Reliance on Antibiotics: Farm operators historically preferred post-outbreak antibiotic treatment over preventive vaccination regimens.
• Government Subsidy Fluctuations: Aquaculture vaccine purchasing demand has been heavily tied to annual government subsidy budget variations.

④ Emerging Turnaround Catalysts

Stricter national eco-friendly seafood certification standards, rigorous antibiotic residue inspection regulations, and the gradual adoption of automated fish injection machines are converging to establish a **structural turning point for aquaculture vaccines**.

[Official References & Sources]
• [Reference 1] DART Repository (http://dart.fss.or.kr): Central Vaccine Periodic Business Reports, 'Section II. Business Description (Main Products & R&D Activities)'.
• [Reference 2] APQA Animal Medical System (https://ehaccp.qia.go.kr): Aquatic Biological Product Licensures for Central Vaccine.
• [Reference 3] Central Vaccine Official Site (http://www.cavac.co.kr): Product Lineup Section (Aquaculture Vaccines).

---

5. Recent Financials & Revenue Trends: Ironclad Balance Sheet vs. Range-Bound Growth

An examination of Central Vaccine's financial statements over recent years reveals a classic **"deep-value asset stock"** profile—exceptionally safe, yet constrained in top-line growth.

Financial Metric	Recent Trajectory & Characteristics	Analysis & Evaluation
Revenue (Sales)	Bound within a range of **35B to 45B KRW** annually	Maintains a solid revenue floor despite livestock industry cycles, but top-line growth remains range-bound.
Operating Profit (OP)	Maintained around **2B to 5B KRW** per year	Margins squeezed by feed-price-driven farm headwinds, raw material inflation, and continuous R&D spending.
Financial Health	Debt ratio **under 30%**, abundant cash reserves	Near zero-debt conservative management; bankruptcy or solvency risk is virtually non-existent.

The primary factor capping top-line expansion has been the **saturation of the domestic livestock vaccine market** alongside seasonal fluctuations in outbreak occurrences. Unlocking exponential growth requires a step-function jump via overseas exports and premium pet/aquaculture offerings.

---

6. Stock Price Trajectory & Valuation: Prolonged Neglect in the Deep Value Zone

Central Vaccine’s stock price chart reflects a lengthy and frustrating consolidation period for long-term investors.

[Central Vaccine Multi-Year Stock Trajectory Summary]
2020–2021 (Biotech/Vaccine sector rally & peak valuation)
  └──▶ Declining trading volume & livestock margin compression
  └──▶ 2022–2026 Present (Downtrend channel & low-volume box-range consolidation)

• Key Causes of Stock Weakness:
  1. Post-COVID capital flight away from small-cap animal health stocks toward AI, Semiconductors, and EV supply chains.
  2. Subdued vaccine purchasing power among domestic swine farms due to high feed grain prices.
  3. Delayed timelines for regulatory approvals and commercialization in major export markets like China.
• Valuation Assessment: The stock currently trades at a Price-to-Book Ratio (PBR) of approximately **0.5x to 0.7x**, representing a deep value discount relative to the intrinsic value of its real estate holdings, net cash, and proprietary biological R&D assets.

---

7. [Personal Investor Perspective & Long-Term Thesis] 3 Turnaround Catalysts for a 4-Year Shareholder

"Despite holding a negative return over a 4-year investment period, my conviction to hold Central Vaccine rests on three structural shift catalysts."

Below are my personal, unedited reflections as a retail shareholder regarding the long-term upside potential of Central Vaccine.

💡 Perspective 1: 4-Year Holding Reflections, R&D Perseverance & China Export Momentum

Enduring negative returns for four years is challenging. However, the reason I refrain from selling is the company's **uncompromising R&D discipline during flat earnings cycles**.

For a biotech enterprise, abandoning R&D is equivalent to forfeiting future existence. Central Vaccine consistently allocates a significant portion of its operating cash flow into next-gen recombinant vaccine pipelines and global clinical trials.

China represents the world's largest hog market with massive demand for PED and PCV2 vaccines. Once local approvals and clinical milestones through Chinese partners or subsidiaries cross the finish line, the resulting export volume will generate immense **operating leverage**. Because R&D functions largely as a fixed cost, incremental export sales directly boost operating profit margins.

💡 Perspective 2: Korea's 'Pet Humanization' Era and High-Margin Pet Vaccine / CMO Expansion

South Korea’s pet culture has transitioned rapidly from traditional pet ownership to full **'Pet Humanization'**, mirroring trends in North America and Western Europe.

[Paradigm Shift in Pet Healthcare]
Past: Basic Pets ──▶ Low-cost remedies, reactive treatment post-illness
Present: Family Members ──▶ Premium preventive vaccines, annual wellness care, low price sensitivity

While livestock vaccine pricing is constrained by farm economics, companion animal vaccines (Canishat, Felishat) command **significantly higher gross margins** due to low price sensitivity among pet owners.

Furthermore, as multinational animal pharmaceutical corporations seek production hubs in East Asia, Central Vaccine’s EU-GMP / KGMP-compliant manufacturing facility positions it as an ideal **Contract Manufacturing Organization (CMO) partner**. Securing global pet vaccine CMO contracts would serve as an immediate re-rating catalyst for the company's valuation multiple.

💡 Perspective 3: K-Food Sashimi/Sushi Culture & Aquaculture Vaccines as an Essential Utility

South Korea exhibits one of the highest per capita seafood consumption rates globally, supported by a deeply rooted **raw fish (sashimi and sushi) dining culture** centered around olive flounder (flatfish).

Consumer standards regarding food safety are stricter than ever. Antibiotic contamination incidents in farmed flounder severely damage consumer trust and farm revenues. Consequently, shifting from chemical treatment to **preemptive vaccination** is the only sustainable pathway for the aquaculture sector.

While manual fish injection has historically delayed adoption, the rollout of automated fish injection equipment and expanding government subsidies for eco-friendly farming will transition **aquaculture vaccines from an optional product into a regulatory and economic necessity**. As vaccine penetration rises across flounder farms, Central Vaccine's aquatic division stands to be revalued as a hidden cash-cow business unit.

---

8. Conclusion & Shareholder Takeaway

Central Vaccine (086960) currently trades like an overlooked asset in a quiet corner of the market. Trading volume remains light, testing the patience of multi-year shareholders.

However, an objective look at the company's core fundamentals reveals three solid pillars:

1. Zero Solvency Risk: Minimal debt and strong net cash reserves provide immunity against macro downturns.
2. Sustained R&D Investment: Reinvesting 7–10% of revenue annually into next-gen biological platforms.
3. Three Distinct Growth Engines: **[Commercialization of Chinese Swine Vaccine Exports] + [Expansion into High-Margin Pet Vaccines & CMOs] + [Aquaculture Vaccine Adoption in Sashimi Supply Chains]**.

Rather than reacting to short-term market noise, long-term investors should monitor R&D milestones, export approvals, and new product commercialization. For patient shareholders, Central Vaccine's R&D pipeline holds the fundamental weight required to drive a meaningful long-term re-rating.